-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FlsIjoEuO3f8Dbssgxdp32xpsmM18sRUGxpacwShMuX5tAUAlVpYMadwwHewyzZV 2GnyyJAOAO5Nbtv5WGuwkQ== 0000950137-04-006936.txt : 20040818 0000950137-04-006936.hdr.sgml : 20040818 20040818164603 ACCESSION NUMBER: 0000950137-04-006936 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20040811 ITEM INFORMATION: Other events FILED AS OF DATE: 20040818 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LA JOLLA PHARMACEUTICAL CO CENTRAL INDEX KEY: 0000920465 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330361285 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-24274 FILM NUMBER: 04984582 BUSINESS ADDRESS: STREET 1: 6455 NANCY RIDGE DR CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8584526600 MAIL ADDRESS: STREET 1: 6455 NANCY RIDGE DR CITY: SAN DIEGO STATE: CA ZIP: 92121 8-K 1 a01193e8vk.htm FORM 8-K e8vk
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 11, 2004

LA JOLLA PHARMACEUTICAL COMPANY

(Exact Name of Registrant as Specified in Charter)
         
Delaware
  0-24274   33-0361285
(State or Other Jurisdiction
  (Commission   (IRS Employer
of Incorporation)
  File Number)   Identification No.)

6455 Nancy Ridge Drive
San Diego, California 92121
(Address of Principal Executive Offices, including Zip Code)

(858) 452-6600
(Registrant’s telephone number, including area code)

 

TABLE OF CONTENTS

Item 5. Other Events and Required FD Disclosure.
SIGNATURES

Table of Contents

Item 5. Other Events and Required FD Disclosure.

     On August 11, 2004, the board of directors of La Jolla Pharmaceutical Company (the “Company”) accepted the resignation of William R. Ringo from the board. Mr. Ringo informed the board that he would be assuming the role of President and CEO of Abgenix, Inc. effective August 30, 2004 and that he desired to retire from the board of directors of the Company in order to focus his efforts on his new positions. Mr. Ringo will continue to serve on the board until September 1, 2004.

 

Table of Contents

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
Date: August 18, 2004 LA JOLLA PHARMACEUTICAL COMPANY  
       
       
  By:   /s/ Gail A. Sloan    
    Gail A. Sloan   
    Vice President Finance, Controller and
Secretary 		  
 

 

-----END PRIVACY-ENHANCED MESSAGE-----